Respiratory muscle training vs control
HRQoL: total score · adults and children with cystic fibrosis
1 finding from 1 review
- no estimate extracted3 studies · 69 participantsVery low
Findings
What do systematic reviews say?
4,678 questions · 4,859 findings · 283 reviews
No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%
Respiratory muscle training vs control
Respiratory muscle function: maximal inspiratory pressure (PImax) · adults and children with cystic fibrosis
1 finding from 1 review
- no estimate extracted4 studies · 87 participantsVery low
Respiratory muscle training vs control
Respiratory muscle function: inspiratory capacity · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings: monoclonal antibody KB001‐A vs placebo
Pulmonary exacerbations · children (12 or over) and adults with cystic fibrosis and lung infection
Summary of findings: monoclonal antibody KB001‐A showed no clear difference in pulmonary exacerbations compared with placebo (low certainty).
1 finding from 1 review
- Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes onlyRR 0.25 [0.03, 2.4]2 studies · 196 participantsLow
Summary of findings: monoclonal antibody KB001‐A vs placebo
Respiratory function number of episodes of a drop in FEV1 (unit of measurement not given) · children (12 or over) and adults with cystic fibrosis and lung infection
It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes respiratory function number of episodes of a drop in FEV1 (unit of… compared with placebo (very low certainty).
1 finding from 1 review
- Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes onlyRR 4.74 [0.28, 79.44]2 studies · 196 participantsVery low
Summary of findings: monoclonal antibody KB001‐A vs placebo
Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection
It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes onlyRR 1.3 [0.9, 1.87]2 studies · 196 participantsVery low
Summary of findings: monoclonal antibody KB001‐A vs placebo
Need for antibiotics time to need for antibiotics · children (12 or over) and adults with cystic fibrosis and lung infection
Summary of findings: monoclonal antibody KB001‐A showed no clear difference in need for antibiotics time to need for antibiotics compared with placebo (moderate certainty).
1 finding from 1 review
- Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes onlyHR 1 [0.69, 1.45]1 study · 169 participantsModerate
Summary of findings: monoclonal antibody KB001‐A vs placebo
QoL · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review
- Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 27 participantsLow
Summary of findings: monoclonal antibody KB001‐A vs placebo
Sputum microbiology · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review
- Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 27 participantsLow
Summary of findings: monoclonal antibody KB001‐A vs placebo
Inflammatory markers · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review
- Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 196 participantsVery low
Summary of findings: oral antioxidants (NAC/GSH) vs placebo
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
2 findings from 1 review
- Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 125 participantsVery low
- Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 62 participantsModerate
Summary of findings: oral antioxidants (NAC/GSH) vs placebo
Quality of life: change from baseline in CFQ‐R · adults and children with cystic fibrosis
1 finding from 1 review
- Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 61 participantsModerate
Summary of findings: oral antioxidants (NAC/GSH) vs placebo
Change in BMI · adults and children with cystic fibrosis
1 finding from 1 review
- Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 62 participantsModerate
Summary of findings: oral antioxidants (NAC/GSH) vs placebo
Time to next exacerbation · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
- Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings: oral antioxidants (NAC/GSH) vs placebo
Adverse events · adults and children with cystic fibrosis
Summary of findings: oral antioxidants (NAC/GSH) showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes onlyOR 2.92 [0.11, 74.05]1 study · 70 participantsModerate
Summary of findings for IV fenoterol bromhydrate vs emergency delivery
Perinatal death or severe morbidity · women with a non‐reassuring fetal heart trace during labour but without uterine tachysystole
The review found no eligible studies for this question.
1 finding from 1 review
- Acute tocolysis for uterine tachysystole or suspected fetal distress 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings for IV fenoterol bromhydrate vs emergency delivery
Fetal or neonatal mortality · women with a non‐reassuring fetal heart trace during labour but without uterine tachysystole
The review found no eligible studies for this question.
1 finding from 1 review
- Acute tocolysis for uterine tachysystole or suspected fetal distress 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Summary of findings for IV fenoterol bromhydrate vs emergency delivery
Caesarean section · women with a non‐reassuring fetal heart trace during labour but without uterine tachysystole
Summary of findings for IV fenoterol bromhydrate probably leads to higher caesarean delivery compared with emergency delivery (moderate certainty).
1 finding from 1 review
- Acute tocolysis for uterine tachysystole or suspected fetal distress 2018 · Cochrane Headline outcomes onlyRR 1.12 [1.04, 1.22]1 study · 390 participantsModerate
Summary of findings for IV fenoterol bromhydrate vs emergency delivery
Apgar score less than 7 at 5 minutes · women with a non‐reassuring fetal heart trace during labour but without uterine tachysystole
Summary of findings for IV fenoterol bromhydrate showed no clear difference in 5‐minute Apgar score < 7 compared with emergency delivery (low certainty).
1 finding from 1 review
- Acute tocolysis for uterine tachysystole or suspected fetal distress 2018 · Cochrane Headline outcomes onlyRR 1.28 [0.35, 4.68]1 study · 390 participantsLow
Summary of findings for IV fenoterol bromhydrate vs emergency delivery
Umbilical artery pH < 7.1 · women with a non‐reassuring fetal heart trace during labour but without uterine tachysystole
Summary of findings for IV fenoterol bromhydrate showed no clear difference in umbilical artery pH < 7.1 compared with emergency delivery (low certainty).
1 finding from 1 review
- Acute tocolysis for uterine tachysystole or suspected fetal distress 2018 · Cochrane Headline outcomes onlyRR 0.68 [0.44, 1.05]1 study · 390 participantsLow